The oncogenic potential of NANOG: An important cancer induction mediator.
Animals
Antineoplastic Agents
/ therapeutic use
Biomarkers, Tumor
/ genetics
Cell Transformation, Neoplastic
/ genetics
Drug Resistance, Neoplasm
Gene Expression Regulation, Neoplastic
Humans
Nanog Homeobox Protein
/ genetics
Neoplasms
/ drug therapy
Neoplastic Stem Cells
/ drug effects
Oncogene Proteins
/ genetics
Signal Transduction
NANOG
cancer
cancer stem cells
signaling pathways
Journal
Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
29
07
2020
revised:
02
09
2020
accepted:
07
09
2020
pubmed:
23
9
2020
medline:
21
9
2021
entrez:
22
9
2020
Statut:
ppublish
Résumé
Cancer stem cells (CSCs) are a unique population in the tumor, but they only comprise 2%-5% of the tumor bulk. Although CSCs share several features with embryonic stem cells, CSCs can give rise to the tumor cells. CSCs overexpress embryonic transcription factor NANOG, which is downregulated in differentiated tissues. This transcription factor confers CSC's stemness, unlimited self-renewal, metastasis, invasiveness, angiogenesis, and drug-resistance with the assistance of WNT, OCT4, SOX2, Hedgehog, BMI-1, and other complexes. NANOG facilitates CSCs development via multiple pathways, like angiogenesis and lessening E-cadherin expression levels, which paves the road for metastasis. Moreover, NANOG represses apoptosis and leads to drug-resistance. This review aims to highlight the pivotal role of NANOG and the pertained pathways in CSCs. Also, this current study intends to demonstrate that targeting NANOG can dimmish the CSCs, sensitize the tumor to chemotherapy, and eradicate the cancer cells.
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
NANOG protein, human
0
Nanog Homeobox Protein
0
Oncogene Proteins
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2443-2458Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Aghajani, M., Mokhtarzadeh, A., Aghebati-Maleki, L., Mansoori, B., Mohammadi, A., Safaei, S., Asadzadeh, Z., Hajiasgharzadeh, K., Khaze Shahgoli, V., & Baradaran, B. (2020). CD133 suppression increases the sensitivity of prostate cancer cells to paclitaxel. Molecular Biology Reports, 47, 3691-3703.
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100(7), 3983-3988.
Aliyari-Serej, Z., Ebrahimi, A., Kazemi, T., Najafi, S., Roshani, E., Ebrahimi-Kalan, M., & Baradaran, B. (2020). Relation between Immune cell response and stemness genes expression in breast cancer; A new approach in NANOG gene and Let7-a expression in breast cancer cell lines. Immunopathologia Persa, 6(2), e21.
Almendro, V., Marusyk, A., & Polyak, K. (2013). Cellular heterogeneity and molecular evolution in cancer. Annual Review of Pathology: Mechanisms of Disease, 8, 277-302.
Andrae, J., Gallini, R., & Betsholtz, C. (2008). Role of platelet-derived growth factors in physiology and medicine. Genes & Development, 22(10), 1276-1312.
Azad, M. B., Chen, Y., & Gibson, S. B. (2009). Regulation of autophagy by reactive oxygen species (ROS): Implications for cancer progression and treatment. Antioxidants & Redox Signaling, 11(4), 777-790.
Baba, T., Convery, P., Matsumura, N., Whitaker, R., Kondoh, E., Perry, T., Fujii, S., Marks, J. R., Berchuck, A., & Murphy, S. K. (2009). Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene, 28(2), 209-218.
Banker, D. E., Mayer, S. J., Li, H. Y., Willman, C. L., Appelbaum, F. R., & Zager, R. A. (2004). Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells. Blood, 104(6), 1816-1824.
Bao, B., Ali, S., Ahmad, A., Azmi, A. S., Li, Y., Banerjee, S., Kong, D., Sethi, S., Aboukameel, A., Padhye, S. B., & Sarkar, F. H. (2012). Hypoxia-induced aggressiveness of pancreatic cancer cells is due to increased expression of VEGF, IL-6 and miR-21, which can be attenuated by CDF treatment. PLoS One, 7(12), e50165.
Basati, G., Mohammadpour, H., & Razavi, A. E. (2020). Association of high expression levels of SOX2, NANOG, and OCT4 in gastric cancer tumor tissues with progression and poor prognosis. Journal of Gastrointestinal Cancer, 51(1), 41-47.
Batlle, E., & Clevers, H. (2017). Cancer stem cells revisited. Nature Medicine, 23(10), 1124-1134.
Baumann, M., Krause, M., & Hill, R. (2008). Exploring the role of cancer stem cells in radioresistance. Nature Reviews Cancer, 8(7), 545-554.
Bhaijee, F., Pepper, D. J., Pitman, K. T., & Bell, D. (2012). Cancer stem cells in head and neck squamous cell carcinoma: A review of current knowledge and future applications. Head & Neck, 34(6), 894-899.
Bhummaphan, N., & Chanvorachote, P. (2015). Gigantol suppresses cancer stem cell-like phenotypes in lung cancer cells. Evidence-Based Complementary and Alternative Medicine, 2015, 836564.
Bonnet, D., & Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3(7), 730-737.
Booth, H. A. F., & Holland, P. W. (2004). Eleven daughters of NANOG. Genomics, 84(2), 229-238.
Borovski, T., Felipe De Sousa, E. M., Vermeulen, L., & Medema, J. P. (2011). Cancer stem cell niche: The place to be. Cancer Research, 71(3), 634-639.
Bourguignon, L. Y., Earle, C., Wong, G., Spevak, C. C., & Krueger, K. (2012). Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. Oncogene, 31(2), 149-160.
Bourguignon, L. Y., Peyrollier, K., Xia, W., & Gilad, E. (2008). Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. Journal of Biological Chemistry, 283(25), 17635-17651.
Bourguignon, L. Y., Spevak, C. C., Wong, G., Xia, W., & Gilad, E. (2009). Hyaluronan-CD44 interaction with protein kinase Cϵ promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. Journal of Biological Chemistry, 284(39), 26533-26546.
Bourguignon, L. Y., Wong, G., Earle, C., & Chen, L. (2012). Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. Journal of Biological Chemistry, 287(39), 32800-32824.
Brabletz, T. (2012). To differentiate or not-Routes towards metastasis. Nature Reviews Cancer, 12(6), 425-436.
Bradshaw, A., Wickremesekera, A., Brasch, H. D., Chibnall, A. M., Davis, P. F., Tan, S. T., & Itinteang, T. (2016). Cancer stem cells in glioblastoma multiforme. Frontiers in Surgery, 3, 48.
Buccarelli, M., Marconi, M., Pacioni, S., De Pascalis, I., D'Alessandris, Q. G., Martini, M., Pallini, R., Ricci-Vitiani, L., & Matarrese, P. (2018). Inhibition of autophagy increases susceptibility of glioblastoma stem cells to temozolomide by igniting ferroptosis. Cell Death & Disease, 9(8), 1-17.
Bunting, K. D., Zhou, S., Lu, T., & Sorrentino, B. P. (2000). Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo. Blood, The Journal of the American Society of Hematology, 96(3), 902-909.
Byers, L. A., Sen, B., Saigal, B., Diao, L., Wang, J., Nanjundan, M., Cascone, T., Mills, G. B., Heymach, J. V., & Johnson, F. M. (2009). Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clinical Cancer Research, 15(22), 6852-6861.
Cao, J., Li, L., Chen, C., Lv, C., Meng, F., Zeng, L., Li, Z., Wu, Q., Zhao, K., Pan, B., Cheng, H., Chen, W., & Xu, K. (2013). RNA interference-mediated silencing of NANOG leads to reduced proliferation and self-renewal, cell cycle arrest and apoptosis in T-cell acute lymphoblastic leukemia cells via the p53 signaling pathway. Leukemia Research, 37(9), 1170-1177.
Carke, M. (2006). Cancer stem cells-Perspectives on current status and future directions. Cancer Research, 66, 9339-9344.
Chambers, I., Colby, D., Robertson, M., Nichols, J., Lee, S., Tweedie, S., & Smith, A. (2003). Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell, 113(5), 643-655.
Chang, D. F., Tsai, S. C., Wang, X. C., Xia, P., Senadheera, D., & Lutzko, C. (2009). Molecular characterization of the human NANOG protein. Stem Cells, 27(4), 812-821.
Chau, C. H., & Figg, W. D. (2012). Angiogenesis inhibitors increase tumor stem cells. Cancer Biology & Therapy, 13(8), 586-587.
Chen, T., Du, J., & Lu, G. (2012). Cell growth arrest and apoptosis induced by Oct4 or Nanog knockdown in mouse embryonic stem cells: a possible role of Trp53. Molecular Biology Reports, 39(2), 1855-1861.
Chiba, T., Miyagi, S., Saraya, A., Aoki, R., Seki, A., Morita, Y., Yonemitsu, Y., Yokosuka, O., Taniguchi, H., Nakauchi, H., & Iwama, A. (2008). The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Research, 68(19), 7742-7749.
Chiou, S.-H., Wang, M.-L., Chou, Y.-T., Chen, C.-J., Hong, C.-F., Hsieh, W.-J., Chang, H. T., Chen, Y. S., Lin, T. W., Hsu, H.-S., & Wu, C. W. (2010). Coexpression of Oct4 and Nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Research, 70(24), 10433-10444.
Cho, E. (2019). NANOG-AKT signaling increases metastatic capacity via stabilizes HDAC1 protein through Chfr inactivation. In: AACR Annual Meeting, Atlanta, GA.
Cioffi, M., D'Alterio, C., Camerlingo, R., Tirino, V., Consales, C., Riccio, A., Ieranò, C., Cecere, S. C., Losito, N. S., Greggi, S., Pignata, S., Pirozzi, G., & Scala, S. (2015). Identification of a distinct population of CD133+ CXCR4+ cancer stem cells in ovarian cancer. Scientific Reports, 5, 10357.
Clarke, M. F., & Fuller, M. (2006). Stem cells and cancer: Two faces of eve. Cell, 124(6), 1111-1115.
Codony-Servat, J., & Rosell, R. (2015). Cancer stem cells and immunoresistance: Clinical implications and solutions. Translational Lung Cancer Research, 4(6), 689.
Cojoc, M., Mäbert, K., Muders, M. H., & Dubrovska, A. (2015). A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms. Seminars in Cancer Biology, 31, 16-27.
Conley, S. J., Gheordunescu, E., Kakarala, P., Newman, B., Korkaya, H., Heath, A. N., Clouthier, S. G., & Wicha, M. S. (2012). Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 109(8), 2784-2789.
Dalerba, P., Cho, R. W., & Clarke, M. F. (2007). Cancer stem cells: Models and concepts. Annual Review of Medicine, 58, 267-284.
Dang, H., Ding, W., Emerson, D., & Rountree, C. B. (2011). Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics. BMC Cancer, 11(1), 396.
Danø, K. (1973). Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochimica et Biophysica Acta, 323(3), 466-483.
Das, B., Pal, B., Bhuyan, R., Li, H., Sarma, A., Gayan, S., Talukdar, J., Sandhya, S., Bhuyan, S., Gogoi, G., Gouw, A. M., Baishya, D., Gotlib, J. R., Kataki, A. C., & Felsher, D. W. (2019). MYC regulates the HIF2α Stemness Pathway via Nanog and Sox2 to maintain self-renewal in cancer stem cells versus non-stem cancer cells. Cancer Research, 79, 4015-4025.
Dean, M., Hamon, Y., & Chimini, G. (2001). The human ATP-binding cassette (ABC) transporter superfamily. Journal of Lipid Research, 42(7), 1007-1017.
Deb-Rinker, P., Ly, D., Jezierski, A., Sikorska, M., & Walker, P. R. (2005). Sequential DNA methylation of the Nanog and Oct-4 upstream regions in human NT2 cells during neuronal differentiation. Journal of Biological Chemistry, 280(8), 6257-6260.
DeSano, J. T., & Xu, L. (2009). MicroRNA regulation of cancer stem cells and therapeutic implications. The AAPS journal, 11(4), 682.
Ding, X., Xu, J., Wang, C., Feng, Q., Wang, Q., Yang, Y., Lu, H., Wang, F., Zhu, K., Li, W., Yan, Q., Gao, S. J., & Lu, C. (2019). Suppression of the SAP18/HDAC1 complex by targeting TRIM56 and Nanog is essential for oncogenic viral FLICE-inhibitory protein-induced acetylation of p65/RelA, NF-κB activation, and promotion of cell invasion and angiogenesis. Cell Death & Differentiation, 26(10), 1970-1986.
Eberle, I., Pless, B., Braun, M., Dingermann, T., & Marschalek, R. (2010). Transcriptional properties of human NANOG1 and NANOG2 in acute leukemic cells. Nucleic Acids Research, 38(16), 5384-5395.
El Hout, M., Cosialls, E., Mehrpour, M., & Hamaï, A. (2020). Crosstalk between autophagy and metabolic regulation of cancer stem cells. Molecular cancer, 19(1), 27.
Eun, K., Ham, S. W., & Kim, H. (2017). Cancer stem cell heterogeneity: Origin and new perspectives on CSC targeting. BMB Reports, 50(3), 117-125.
Eyler, C. E., & Rich, J. N. (2008). Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 26(17), 2839-2845.
Felipe De Sousa, E. M., Vermeulen, L., Fessler, E., & Medema, J. P. (2013). Cancer heterogeneity-A multifaceted view. EMBO Reports, 14(8), 686-695.
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D., Gottesman, M., & Pastan, I. (1987). Expression of a multidrug-resistance gene in human tumors and tissues. Proceedings of the National Academy of Sciences of the United States of America, 84(1), 265-269.
Folkman, J. (1971). Tumor angiogenesis: Therapeutic implications. New England Journal of Medicine, 285(21), 1182-1186.
Folkman, J. (2002). Role of angiogenesis in tumor growth and metastasis. Seminars in Oncology, 29, 15-18.
Gangemi, R., Paleari, L., Orengo, A. M., Cesario, A., Chessa, L., Ferrini, S., & Russo, P. (2009). Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Current Medicinal Chemistry, 16(14), 1688-1703.
Garcia-Mayea, Y., Mir, C., Masson, F., Paciucci, R., & LLeonart, M. (2020). Insights into new mechanisms and models of cancer stem cell multidrug resistance. Seminars in Cancer Biology, 60, 166-180.
Gawlik-Rzemieniewska, N., & Bednarek, I. (2016). The role of NANOG transcriptional factor in the development of malignant phenotype of cancer cells. Cancer Biology & Therapy, 17(1), 1-10.
Gillis, A., Stoop, H., Biermann, K., van Gurp, R. J. H. L. M., Swartzman, E., Cribbes, S., Ferlinz, A., Shannon, M., Oosterhuis, J. W., & Looijenga, L. H. J. (2011). Expression and interdependencies of pluripotency factors LIN28, OCT3/4, NANOG and SOX2 in human testicular germ cells and tumours of the testis. International Journal of Andrology, 34(4 Pt 2), e160-e174.
Ginestier, C., Hur, M. H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C. G., Liu, S., Schott, A., Hayes, D., Birnbaum, D., Wicha, M. S., & Dontu, G. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 1(5), 555-567.
Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S.-L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G. M., Lieber, M., Cossman, J., Gottesman, M. M., & Pastan, I. (1989). Expression of multidrug resistance gene in human cancers. Journal of the National Cancer Institute, 81(2), 116-124.
Gong, S., Li, Q., Jeter, C. R., Fan, Q., Tang, D. G., & Liu, B. (2015). Regulation of NANOG in cancer cells. Molecular Carcinogenesis, 54(9), 679-687.
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002). Multidrug resistance in cancer: Role of ATP-dependent transporters. Nature Reviews Cancer, 2(1), 48-58.
Grandela, C., Pera, M., & Wolvetang, E. (2008). p53 is required for etoposide-induced apoptosis of human embryonic stem cells. Stem Cell Research, 1(2), 116-128.
Grubelnik, G., Boštjančič, E., Pavlič, A., Kos, M., & Zidar, N. (2020). NANOG expression in human development and cancerogenesis. Experimental Biology and Medicine, 245(5), 456-464.
Guan, B., Mu, L., Zhang, L., Wang, K., Tian, J., Xu, S., Wang, X., He, D., & Du, Y. (2018). MicroRNA-218 inhibits the migration, epithelial-mesenchymal transition and cancer stem cell properties of prostate cancer cells. Oncology Letters, 16(2), 1821-1826.
Han, M.-l., Wang, F., Gu, Y.-T., Pei, X.-H., Ge, X., Guo, G.-C, Li, L., Duan, X., Zhu, M.-Z., & Wang, Y.-M. (2016). MicroR-760 suppresses cancer stem cell subpopulation and breast cancer cell proliferation and metastasis: By down-regulating NANOG. Biomedicine & Pharmacotherapy, 80, 304-310.
Han, J., Zhang, F., Yu, M., Zhao, P., Ji, W., Zhang, H., Wu, B., Wang, Y., & Niu, R. (2012). RNA interference-mediated silencing of NANOG reduces cell proliferation and induces G0/G1 cell cycle arrest in breast cancer cells. Cancer Letters, 321(1), 80-88.
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646-674.
Hart, S., Ganeshaguru, K., Hoffbrand, A., Prentice, H., & Mehta, A. (1994). Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia. Leukemia, 8(12), 2163-2168.
Hasmim, M., Janji, B., Khaled, M., Noman, M. Z., Louache, F., Bordereaux, D., Abderamane, A., Baud, V., Mami-Chouaib, F., & Chouaib, S. (2017). Cutting edge: NANOG activates autophagy under hypoxic stress by binding to BNIP3L promoter. The Journal of Immunology, 198(4), 1423-1428.
Hen, O., & Barkan, D. (2020). Dormant disseminated tumor cells and cancer stem/progenitor-like cells: Similarities and opportunities. Seminars in Cancer Biology, 60, 157-165.
Ho, M. M., Ng, A. V., Lam, S., & Hung, J. Y. (2007). Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Research, 67(10), 4827-4833.
Hoei-Hansen, C. E., Almstrup, K., Nielsen, J. E., Brask Sonne, S., Graem, N., Skakkebaek, N. E., Leffers, H., & Rajpert-De Meyts, E. (2005). Stem cell pluripotency factor NANOG is expressed in human fetal gonocytes, testicular carcinoma in situ and germ cell tumours. Histopathology, 47(1), 48-56.
Hu, C., Xu, L., Liang, S., Zhang, Z., Zhang, Y., & Zhang, F. (2016). Lentivirus-mediated shRNA targeting Nanog inhibits cell proliferation and attenuates cancer stem cell activities in breast cancer. Journal of Drug Targeting, 24(5), 422-432.
Huang, C., Yoon, C., Zhou, X.-H., Zhou, Y.-C., Zhou, W.-W., Liu, H., Yang, X., Lu, J., Lee, S. Y., & Huang, K. (2020). ERK1/2-Nanog signaling pathway enhances CD44 (+) cancer stem-like cell phenotypes and epithelial-to-mesenchymal transition in head and neck squamous cell carcinomas. Cell Death & Disease, 11(4), 1-14.
Huang, C.-E., Yu, C.-C., Hu, F.-W., Chou, M.-Y., & Tsai, L.-L. (2014). Enhanced chemosensitivity by targeting Nanog in head and neck squamous cell carcinomas. International Journal of Molecular Sciences, 15(9), 14935-14948.
Huang, E. H., Hynes, M. J., Zhang, T., Ginestier, C., Dontu, G., Appelman, H., Fields, J. Z., Wicha, M. S., & Boman, B. M. (2009). Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Research, 69(8), 3382-3389.
Huang, Z.-J., You, J., Luo, W.-Y., Chen, B.-S., Feng, Q.-Z., Wu, B.-L., Jiang, L., & Luo, Q. (2015). Reduced tumorigenicity and drug resistance through the downregulation of octamer-binding protein 4 and Nanog transcriptional factor expression in human breast stem cells. Molecular Medicine Reports, 11(3), 1647-1654.
Hurt, E. M., Kawasaki, B. T., Klarmann, G. J., Thomas, S. B., & Farrar, W. L. (2008). CD44+ CD24− prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. British Journal of Cancer, 98(4), 756-765.
Iv Santaliz-Ruiz, L. E., Xie, X., Old, M., Teknos, T. N., & Pan, Q. (2014). Emerging role of nanog in tumorigenesis and cancer stem cells. International Journal of Cancer, 135(12), 2741-2748.
Jeter, C. R., Badeaux, M., Choy, G., Chandra, D., Patrawala, L., Liu, C., Calhoun-Davis, T., Zaehres, H., Daley, G. Q., & Tang, D. G. (2009). Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells, 27(5), 993-1005.
Ji, Z., Xu, C., & Qiu, Y. (2019). Effect of the nanog gene on proliferation and apoptosis in the pancreatic cancer cell line PANC-1. Acta Medica Mediterranea, 35(4), 2151-2157.
de Jonge-Peeters, S. D., Kuipers, F., de Vries, E. G., & Vellenga, E. (2007). ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Critical Reviews in Oncology/Hematology, 62(3), 214-226.
Kantara, C., O'Connell, M., Sarkar, S., Moya, S., Ullrich, R., & Singh, P. (2014). Curcumin promotes autophagic survival of a subset of colon cancer stem cells, which are ablated by DCLK1-siRNA. Cancer Research, 74(9), 2487-2498.
Katsuno, Y., Hanyu, A., Kanda, H., Ishikawa, Y., Akiyama, F., Iwase, T., Ogata, E., Ehata, S., Miyazono, K., & Imamura, T. (2008). Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene, 27(49), 6322-6333.
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P.dL., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994). Specific association of human telomerase activity with immortal cells and cancer. Science, 266(5193), 2011-2015.
Kim, S., Cho, H., Hong, S.-O., Oh, S. J., Lee, H.-J., Cho, E., Woo, S. R., Song, J. S., Chung, J.-Y., Son, S. W., Yoon, S. M., Jeon, Y.-M., Jeon, S., Yee, C., Lee, K.-M., Hewitt, S.M., Kim, J.-H., Song, K.-H., & Kim, T. W. (2020). LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cells. Autophagy. https://doi.org/10.1080/15548627.2020.1805214
Kreso, A., & Dick, J. E. (2014). Evolution of the cancer stem cell model. Cell Stem Cell, 14(3), 275-291.
Kreso, A., O'Brien, C. A., Van Galen, P., Gan, O. I., Notta, F., Brown, A. M., Ng, K., Ma, J., Wienholds, E., Dunant, C., Pollett, A., Gallinger, S., McPherson, J., Mullighan, C. G., Shibata, D., & Dick, J. E. (2013). Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science, 339(6119), 543-548.
Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 367(6464), 645-648.
Lau, E. Y.-T., Ho, N. P.-Y., & Lee, T. K.-W. (2017). Cancer stem cells and their microenvironment: Biology and therapeutic implications. Stem Cells International, 2017, 1-11.
Lee, H.-J., Noh, K. H., Lee, Y.-H., Song, K.-H., Oh, S. J., Kim, S. Y., & Kim, T. W. (2015). NANOG signaling promotes metastatic capability of immunoedited tumor cells. Clinical & Experimental Metastasis, 32(5), 429-439.
Lee, M., Nam, E. J., Kim, S. W., Kim, S., Kim, J. H., & Kim, Y. T. (2012). Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma. International Journal of Gynecologic Cancer, 22(9), 1489-1496.
Lee, S. Y., Jeong, E. K., Ju, M. K., Jeon, H. M., Kim, M. Y., Kim, C. H., Park, H. G., Han, S. I., & Kang, H. S. (2017). Induction of metastasis, cancer stem cell phenotype, and oncogenic metabolism in cancer cells by ionizing radiation. Molecular Cancer, 16(1), 10.
Lee, T. K. W., Castilho, A., Cheung, V. C. H., Tang, K. H., Ma, S., & Ng, I. O. L. (2011). CD24+ liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell, 9(1), 50-63.
Leith, C. P., Kopecky, K. J., Godwin, J., McConnell, T., Slovak, M. L., Chen, I.-M., Head, D. R., Appelbaum, F. R., & Willman, C. L. (1997). Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood, The Journal of the American Society of Hematology, 89(9), 3323-3329.
Leonard, G. D., Fojo, T., & Bates, S. E. (2003). The role of ABC transporters in clinical practice. The Oncologist, 8(5), 411-424.
Li, H. Y., Appelbaum, F. R., Willman, C. L., Zager, R. A., & Banker, D. E. (2003). Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood, The Journal of the American Society of Hematology, 101(9), 3628-3634.
Li, J., Hu, S., Wang, L.Y., Zhang, X., Zhou, X., Yang, B., Li, J. H., Xiong, J., Liu, N., Li, Y., Wu, Y. Z., & Zheng, Q. C. (2017). Autophagy-dependent generation of Axin2+ cancer stem-like cells promotes hepatocarcinogenesis in liver cirrhosis. Oncogene, 36(48), 6725-6737.
Li, Y., & Laterra, J. (2012). Cancer stem cells: Distinct entities or dynamically regulated phenotypes? Cancer Research, 72(3), 576-580.
Liao, W.-Y., Liaw, C.-C., Huang, Y.-C., Han, H.-Y., Hsu, H.-W., Hwang, S.-M., Kuo, S. C., & Shen, C.-N. (2013). Cyclohexylmethyl flavonoids suppress propagation of breast cancer stem cells via downregulation of NANOG. Evidence-Based Complementary and Alternative Medicine, 2013, 170261.
Ling, G.-Q., Chen, D.-B., Wang, B.-Q., & Zhang, L.-S. (2012). Expression of the pluripotency markers Oct3/4, Nanog and Sox2 in human breast cancer cell lines. Oncology Letters, 4(6), 1264-1268.
Liu, C.-W., Li, C.-H., Peng, Y.-J., Cheng, Y.-W., Chen, H.-W., Liao, P.-L., Kang, J. J., & Yeng, M.-H. (2014). Snail regulates Nanog status during the epithelial-mesenchymal transition via the Smad1/Akt/GSK3β signaling pathway in non-small-cell lung cancer. Oncotarget, 5(11), 3880-3894.
Liu, H., He, Z., von Rütte, T., Yousefi, S., Hunger, R. E., & Simon, H.-U. (2013). Down-regulation of autophagy-related protein 5 (ATG5) contributes to the pathogenesis of early-stage cutaneous melanoma. Science Translational Medicine, 5(202), 202ra123.
Liu, K., Lee, J., Kim, J. Y., Wang, L., Tian, Y., Chan, S. T., Cho, C., Machida, K., Chen, D., & Ou, J.-H. J. (2017). Mitophagy controls the activities of tumor suppressor p53 to regulate hepatic cancer stem cells. Molecular Cell, 68(2), 281-292.e285.
Liu, S., Cheng, K., Zhang, H., Kong, R., Wang, S., Mao, C., & Liu, S. (2020). Methylation status of the Nanog promoter determines the switch between cancer cells and cancer stem cells. Advanced Science, 7(5), 1903035.
Liu, S., Dontu, G., Mantle, I. D., Patel, S., Ahn, N.-S., Jackson, K. W., Suri, P., & Wicha, M. S. (2006). Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Research, 66(12), 6063-6071.
Liu, S., Sun, J., Cai, B., Xi, X., Yang, L., Zhang, Z., Feng, Y., & Sun, Y. (2016). NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer. Tumor Biology, 37(7), 9671-9680.
Lu, D., Shi, H.-C., Wang, Z.-X., Gu, X.-W., & Zeng, Y. (2011). Multidrug resistance-associated biomarkers PGP, GST-π, Topo-II and LRP as prognostic factors in primary ovarian carcinoma. British Journal of Biomedical Science, 68(2), 69-74.
Lu, X., Mazur, S. J., Lin, T., Appella, E., & Xu, Y. (2014). The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis. Oncogene, 33(20), 2655-2664.
Lukacs, R. U., Memarzadeh, S., Wu, H., & Witte, O. N. (2010). Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell, 7(6), 682-693.
Mansoori, B., Mohammadi, A., Asadzadeh, Z., Shirjang, S., Minouei, M., Abedi Gaballu, F., Shajari, N., Kazemi, T., Gjerstorff, M. F., Duijf, P. H.G., & Baradaran, B. (2019). HMGA2 and Bach-1 cooperate to promote breast cancer cell malignancy. Journal of Cellular Physiology, 234(10), 17714-17726.
Markowska, A., Sajdak, S., Markowska, J., & Huczyński, A. (2017). Angiogenesis and cancer stem cells: New perspectives on therapy of ovarian cancer. European Journal of Medicinal Chemistry, 142, 87-94.
Marquardt, J. U., Galle, P. R., & Teufel, A. (2012). Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): An emerging field for advanced technologies. Journal of Hepatology, 56(1), 267-275.
Matak, D., Brodaczewska, K. K., Szczylik, C., Koch, I., Myszczyszyn, A., Lipiec, M., Lewicki, S., Szymanski, L., Zdanowski, R., & Czarnecka, A. M. (2017). Functional significance of CD105-positive cells in papillary renal cell carcinoma. BMC Cancer, 17(1), 1-17.
Maycotte, P., Jones, K. L., Goodall, M. L., Thorburn, J., & Thorburn, A. (2015). Autophagy supports breast cancer stem cell maintenance by regulating IL6 secretion. Molecular Cancer Research, 13(4), 651-658.
Medema, J. P. (2013). Cancer stem cells: The challenges ahead. Nature Cell Biology, 15(4), 338-344.
Meng, E., Long, B., Sullivan, P., McClellan, S., Finan, M. A., Reed, E., Shevde, L., & Rocconi, R. P. (2012). CD44+/CD24− ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clinical & Experimental Metastasis, 29(8), 939-948.
Meng, Q., Xu, J., Liang, C., Liu, J., Hua, J., Zhang, Y., Ni, Q., Shi, S., & Yu, X. (2018). GPx1 is involved in the induction of protective autophagy in pancreatic cancer cells in response to glucose deprivation. Cell Death & Disease, 9(12), 1187.
Miki, J., Furusato, B., Li, H., Gu, Y., Takahashi, H., Egawa, S., Sesterhenn, I. A., McLeod, D. G., Srivastava, S., & Rhim, J. S. (2007). Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-Immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Research, 67(7), 3153-3161.
Mimeault, M., & Batra, S. K. (2010). New advances on critical implications of tumor-and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence. Histology and Histopathology, 25(8), 1057.
Mitsui, K., Tokuzawa, Y., Itoh, H., Segawa, K., Murakami, M., Takahashi, K., Maruyama, M., Maeda, M., & Yamanaka, S. (2003). The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell, 113(5), 631-642.
Miyake, H., Hara, I., Yamanaka, K., Gohji, K., Arakawa, S., & Kamidono, S. (1998). Expression patterns of CD44 adhesion molecule in testicular germ cell tumors and normal testes. The American Journal of Pathology, 152(5), 1157.
Miyazawa, K., Tanaka, T., Nakai, D., Morita, N., & Suzuki, K. (2014). Immunohistochemical expression of four different stem cell markers in prostate cancer: High expression of NANOG in conjunction with hypoxia-inducible factor-1α expression is involved in prostate epithelial malignancy. Oncology Letters, 8(3), 985-992.
Moretto-Zita, M., Jin, H., Shen, Z., Zhao, T., Briggs, S. P., & Xu, Y. (2010). Phosphorylation stabilizes Nanog by promoting its interaction with Pin1. Proceedings of the National Academy of Sciences of the United States of America, 107(30), 13312-13317.
Moshaver, B., Rhenen, A., Kelder, A., Pol, M., Terwijn, M., Bachas, C., Westra, A. H., Ossenkoppele, G. J., Zweegman, S., & Schuurhuis, G. J. (2008). Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells, 26(12), 3059-3067.
Nakajima, S., Doi, R., Toyoda, E., Tsuji, S., Wada, M., Koizumi, M., Tulachan, S. S., Ito, D, Kami, K., Mori, T., Kawaguchi, Y, Fujimoto, K., Hosotani, R., & Imamura, M. (2004). N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clinical Cancer Research, 10(12), 4125-4133.
Nassar, D., & Blanpain, C. (2016). Cancer stem cells: basic concepts and therapeutic implications. Annual Review of Pathology: Mechanisms of Disease, 11, 47-76.
Nawrocki-Raby, B., Gilles, C., Polette, M., Martinella-Catusse, C., Bonnet, N., Puchelle, E., Foidart, J.M., Van Roy, F., & Birembaut, P. (2003). E-Cadherin mediates MMP down-regulation in highly invasive bronchial tumor cells. The American Journal of Pathology, 163(2), 653-661.
Neal, C. L., Henderson, V., Smith, B. N., McKeithen, D., Graham, T., Vo, B. T., & Odero-Marah, V. A. (2012). Snail transcription factor negatively regulates maspin tumor suppressor in human prostate cancer cells. BMC Cancer, 12(1), 336.
Nguyen, L. V., Vanner, R., Dirks, P., & Eaves, C. J. (2012). Cancer stem cells: An evolving concept. Nature Reviews Cancer, 12(2), 133-143.
Nishida, N., Yano, H., Nishida, T., Kamura, T., & Kojiro, M. (2006). Angiogenesis in cancer. Vascular Health and Risk Management, 2(3), 213-219.
Niu, C. S., Yang, Y., & Cheng, C.-D. (2013). MiR-134 regulates the proliferation and invasion of glioblastoma cells by reducing Nanog expression. International Journal of Oncology, 42(5), 1533-1540.
Noh, K. H., Kim, B. W., Song, K.-H., Cho, H., Lee, Y.-H., Kim, J.-H., Hewitt, S. M., Seong, S.-Y., Mao, C.-P, Wu, T.-C., & Kim, T. W. (2012). Nanog signaling in cancer promotes stem-like phenotype and immune evasion. The Journal of Clinical Investigation, 122(11), 4077-4093.
O'Brien, C. A., Kreso, A., & Jamieson, C. H. (2010). Cancer stem cells and self-renewal. Clinical Cancer Research, 16(12), 3113-3120.
O'Day, E., & Lal, A. (2010). MicroRNAs and their target gene networks in breast cancer. Breast Cancer Research, 12(2), 201.
Odorico, J. S., Kaufman, D. S., & Thomson, J. A. (2001). Multilineage differentiation from human embryonic stem cell lines. Stem Cells, 19(3), 193-204.
Ojha, R., Jha, V., Singh, S. K., & Bhattacharyya, S. (2014). Autophagy inhibition suppresses the tumorigenic potential of cancer stem cell enriched side population in bladder cancer. Biochimica et Biophysica Acta, 1842(11), 2073-2086.
Oka, H., Shiozaki, H., Kobayashi, K., Inoue, M., Tahara, H., Kobayashi, T., Takatsuka, Y., Matsuyoshi, N., Hirano, S., Takeichi, M., & Mori, T. (1993). Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Research, 53(7), 1696-1701.
Okudela, K., Woo, T., Mitsui, H., Tajiri, M., Masuda, M., & Ohashi, K. (2012). Expression of the potential cancer stem cell markers, CD 133, CD 44, ALDH 1, and β-catenin, in primary lung adenocarcinoma-Their prognostic significance. Pathology International, 62(12), 792-801.
Paduch, R. (2016). The role of lymphangiogenesis and angiogenesis in tumor metastasis. Cellular Oncology, 39(5), 397-410.
Paranjape, A. N., Balaji, S. A., Mandal, T., Krushik, E. V., Nagaraj, P., Mukherjee, G., & Rangarajan, A. (2014). Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog. BMC Cancer, 14(1), 785.
Pattabiraman, D. R., & Weinberg, R. A. (2014). Tackling the cancer stem cells-What challenges do they pose? Nature Reviews Drug Discovery, 13(7), 497-512.
Peng, F., Wang, J.-H., Fan, W.-J., Meng, Y.-T., Li, M.-M., Li, T.-T., Cui, B., Wang, H. F., Zhao, Y., An, F., Guo, T., Liu, X. F., Zhang, L., Lv, L., Lv, D. K., Xu, L. Z., Xie, J. J., Lin, W. X., Lam, E. W, … Liu, Q. (2018). Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia. Oncogene, 37(8), 1062-1074.
Peng, Q., Qin, J., Zhang, Y., Cheng, X., Wang, X., Lu, W., Xie, X., & Zhang, S. (2017). Autophagy maintains the stemness of ovarian cancer stem cells by FOXA2. Journal of Experimental & Clinical Cancer Research, 36(1), 1-12.
Piestun, D., Kochupurakkal, B. S., Jacob-Hirsch, J., Zeligson, S., Koudritsky, M., Domany, E., Amariglio, N., Rechavi, G., & Givol, D. (2006). Nanog transforms NIH3T3 cells and targets cell-type restricted genes. Biochemical and Biophysical Research Communications, 343(1), 279-285.
Podberezin, M., Wen, J., & Chang, C.-C. (2013). Cancer stem cells: A review of potential clinical applications. Archives of Pathology and Laboratory Medicine, 137(8), 1111-1116.
Prasad, S., Ramachandran, S., Gupta, N., Kaushik, I., & Srivastava, S. K. (2020). Cancer cells stemness: A doorstep to targeted therapy. Biochimica et Biophysica Acta, 1866(4), 165424.
Prince, M. E., Sivanandan, R., Kaczorowski, A., Wolf, G.T., Kaplan, M. J., Dalerba, P., Weissman, I. L., Clarke, M. F., & Ailles, L. E. (2007). Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 104(3), 973-978.
Proctor, E., Waghray, M., Lee, C. J., Heidt, D. G., Yalamanchili, M., Li, C., Bednar, F., & Simeone, D. M. (2013). Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma. PLoS One, 8(2), e55820.
Qu, X., Yu, J., Bhagat, G., Furuya, N., Hibshoosh, H., Troxel, A., Rosen, J., Eskelinen, E. L., Mizushima, N., Ohsumi, Y., Cattoretti, G., & Levine, B. (2003). Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. The Journal of Clinical Investigation, 112(12), 1809-1820.
Rasti, A., Mehrazma, M., Madjd, Z., Abolhasani, M., Zanjani, L. S., & Asgari, M. (2018). Co-expression of cancer stem cell markers OCT4 and NANOG predicts poor prognosis in renal cell carcinomas. Scientific Reports, 8(1), 1-11.
Rausch, V., Liu, L., Apel, A., Rettig, T., Gladkich, J., Labsch, S., Kallifatidis, G., Kaczorowski, A., Groth, A., Gross, W., Gebhard, M. M., Schemmer, P., Werner, J., Salnikov, A. V., Zentgraf, H., Büchler, M. W., & Herr, I. (2012). Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment. The Journal of Pathology, 227(3), 325-335.
Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000). Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes & Development, 14(1), 34-44.
Resetkova, E., Reis-Filho, J. S., Jain, R. K., Mehta, R., Thorat, M. A., Nakshatri, H., & Badve, S. (2010). Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment. Breast Cancer Research and Treatment, 123(1), 97-108.
Reya, T., & Clevers, H. (2005). Wnt signalling in stem cells and cancer. Nature, 434(7035), 843-850.
Ross, D. D. (2004). Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Practice & Research Clinical Haematology, 17(4), 641-651.
Ross, D. D., Karp, J. E., Chen, T. T., & Doyle, L. A. (2000). Expression of breast cancer resistance protein in blast cells from patients with acute leukemia: Presented in part at the Fortieth Annual Meeting of the American Society of Hematology, Miami Beach, FL, December 4-8, 1998. Blood, The Journal of the American Society of Hematology, 96(1), 365-368.
Russo, A., Terrasi, M., Agnese, V., Santini, D., & Bazan, V. (2006). Apoptosis: A relevant tool for anticancer therapy. Annals of Oncology, 17, vii115-vii123.
Saeednejad Zanjani, L., Madjd, Z., Abolhasani, M., Shariftabrizi, A., Rasti, A., & Asgari, M. (2018). Expression of CD105 cancer stem cell marker in three subtypes of renal cell carcinoma. Cancer Biomarkers, 21(4), 821-837.
Saga, K., Park, J., Nimura, K., Kawamura, N., Ishibashi, A., Nonomura, N., & Kaneda, Y. (2019). NANOG helps cancer cells escape NK cell attack by downregulating ICAM1 during tumorigenesis. Journal of Experimental & Clinical Cancer Research, 38(1), 1-13.
Sammar, M., Gulbins, E., Hilbert, K., Lang, F., & Altevogt, P. (1997). Mouse CD24 as a signaling molecule for integrin-mediated cell binding: Functional and physical association with src-kinases. Biochemical and Biophysical Research Communications, 234(2), 330-334.
Saroufim, A., Messai, Y., Hasmim, M., Rioux, N., Iacovelli, R., Verhoest, G., Bensalah, K., Patard, J.-J., Albiges, L., Azzarone, B., Escudier, B., & Chouaib, S. (2014). Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma. British Journal of Cancer, 110(7), 1778-1784.
Sato, A., Okada, M., Shibuya, K., Watanabe, E., Seino, S., Suzuki, K., Narita, Y., Shibui, S., Kayama, T, & Kitanaka, C. (2013). Resveratrol promotes proteasome-dependent degradation of Nanog via p53 activation and induces differentiation of glioma stem cells. Stem Cell Research, 11(1), 601-610.
Schimmer, A. D. (2008). Apoptosis in leukemia: From molecular pathways to targeted therapies. Best Practice & Research Clinical Haematology, 21(1), 5-11.
Shan, J., Shen, J., Liu, L., Xia, F., Xu, C., Duan, G., Xu, Y., Ma, Q., Yang, Z., Zhang, Q., Ma, L., Liu, J., Xu, S., Yan, X., Bie, P., Cui, Y., Bian, X. W., & Qian, C. (2012). Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology, 56(3), 1004-1014.
Sharif, T., Martell, E., Dai, C., Kennedy, B. E., Murphy, P., Clements, D. R., Kim, Y., Lee, P. W. K., & Gujar, S. A. (2017). Autophagic homeostasis is required for the pluripotency of cancer stem cells. Autophagy, 13(2), 264-284.
Shi, P., Liu, W., Wang, H., Li, F., Zhang, H., Wu, Y., Kong, Y., Zhou, Z., Wang, C., Chen, W., Liu, R., & Chen, C. (2017). Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation. Cell Discovery, 3(1), 1-13.
Shimizu, S., & Tsujimoto, Y. (2000). Proapoptotic BH3-only Bcl-2 family members induce cytochrome c release, but not mitochondrial membrane potential loss, and do not directly modulate voltage-dependent anion channel activity. Proceedings of the National Academy of Sciences of the United States of America, 97(2), 577-582.
Shirjang, S., Mansoori, B., Asghari, S., Duijf, P. H., Mohammadi, A., Gjerstorff, M., & Baradaran, B. (2019). MicroRNAs in cancer cell death pathways: Apoptosis and necroptosis. Free Radical Biology and Medicine, 139, 1-15.
Shriwas, O., Priyadarshini, M., Samal, S. K., Rath, R., Panda, S., Das Majumdar, S. K. D., Muduly, D. K., Botlagunta, M., & Dash, R. (2020). DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m 6 A-demethylation of FOXM1 and NANOG. Apoptosis, 25, 1-14.
Singh, A., & Settleman, J. (2010). EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene, 29(34), 4741-4751.
Singh, S. K., Clarke, I. D., Terasaki, M., Bonn, V. E., Hawkins, C., Squire, J., & Dirks, P. B. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Research, 63(18), 5821-5828.
Siu, M. K., Wong, E. S., Chan, H. Y., Ngan, H. Y., Chan, K. Y., & Cheung, A. N. (2008). Overexpression of NANOG in gestational trophoblastic diseases: effect on apoptosis, cell invasion, and clinical outcome. The American Journal of Pathology, 173(4), 1165-1172.
Siu, M. K. Y., Wong, E. S. Y., Kong, D. S. H., Chan, H. Y., Jiang, L., Wong, O. G., Lam, E. W.-F., Chan, K. K., Ngan, H.Y., Le, X.-F., & Cheung, AN (2013). Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene, 32(30), 3500-3509.
Song, Y.-J., Zhang, S.-S., Guo, X.-L., Sun, K., Han, Z.-P., Li, R., Zhao, Q.-D., Deng, W.-J., Xie, X.-Q., Zhang, J.-W., Wu, M.-C., & Wei, L.-X. (2013). Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment. Cancer Letters, 339(1), 70-81.
Soni, P., Qayoom, S., Husain, N., Kumar, P., Chandra, A., Ojha, B. K., & Gupta, R. K. (2017). CD24 and nanog expression in stem cells in glioblastoma: correlation with response to chemoradiation and overall survival. Asian Pacific Journal of Cancer Prevention, 18(8), 2215.
Srinual, S., Chanvorachote, P., & Pongrakhananon, V. (2017). Suppression of cancer stem-like phenotypes in NCI-H460 lung cancer cells by vanillin through an Akt-dependent pathway. International Journal of Oncology, 50(4), 1341-1351.
Stacker, S. A., Baldwin, M. E., & Achen, M. G. (2002). The role of tumor lymphangiogenesis in metastatic spread. The FASEB Journal, 16(9), 922-934.
Sun, C., Sun, L., Jiang, K., Gao, D.-M., Kang, X.-N., Wang, C., Zhang, S., Huang, S., Qin, X., Li, Y., & Liu, Y. K. (2013). NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through NODAL/SMAD3 signaling pathway. The International Journal of Biochemistry & Cell Biology, 45(6), 1099-1108.
Sun, K., Deng, W., Zhang, S., Cai, N., Jiao, S., Song, J., & Wei, L. (2013). Paradoxical roles of autophagy in different stages of tumorigenesis: protector for normal or cancer cells. Cell & Bioscience, 3(1), 1-8.
Suzuki, A., Raya, Á., Kawakami, Y., Morita, M., Matsui, T., Nakashima, K., Gage, F. H., Rodríguez-Esteban, C., & Belmonte, J. C. I. (2006). Nanog binds to Smad1 and blocks bone morphogenetic protein-induced differentiation of embryonic stem cells. Proceedings of the National Academy of Sciences of the United States of America, 103(27), 10294-10299.
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131(5), 861-872.
Takebe, N., Harris, P. J., Warren, R. Q., & Ivy, S. P. (2011). Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nature Reviews Clinical Oncology, 8(2), 97-106.
Tang, S., Xiang, T., Huang, S., Zhou, J., Wang, Z., Xie, R., Long, H., & Zhu, B. (2016). Ovarian cancer stem-like cells differentiate into endothelial cells and participate in tumor angiogenesis through autocrine CCL5 signaling. Cancer Letters, 376(1), 137-147.
Terstappen, L., Safford, M., Unterhalt, M., Könemann, S., Zurlutter, K., Piechotka, K., Drescher, M., Aul, C., Büchner, T., & Hiddemann, W. (1992). Flow cytometric characterization of acute myeloid leukemia: IV. Comparison to the differentiation pathway of normal hematopoietic progenitor cells. Leukemia, 6(10), 993-1000.
Thiagarajan, P. S., Sinyuk, M., Turaga, S. M., Mulkearns-Hubert, E. E., Hale, J. S., Rao, V., Demelash, A, Saygin, C., China, A, Alban, T. J., Hitomi, M., Torre-Healy, L. A., Alvarado, A. G., Jarrar, A., Wiechert, A., Adorno-Cruz, V., Fox, P. L., Calhoun, B. C., Guan, J. L., … Lathia, J. D. (2018). Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nature Communications, 9(1), 578.
Tiwari, N., Gheldof, A., Tatari, M., & Christofori, G. (2012). EMT as the ultimate survival mechanism of cancer cells. Seminars in Cancer Biology, 22, 194-207.
Toh, T. B., Lim, J. J., & Chow, E. K.-H. (2017). Epigenetics in cancer stem cells. Molecular Cancer, 16(1), 29.
Wang, H., Liu, B., Wang, J., Li, J., Gong, Y., Li, S., Wang, C., Cui, B., Xue, X., Yang, M., Fan, W., Kang, Z., Kamran, M., Xu, J., Tian, P., Luo, Y., Hou, Z., Dong, L., Ren, Y., … Liu, Q. (2017). Reduction of NANOG mediates the inhibitory effect of aspirin on tumor growth and stemness in colorectal cancer. Cellular Physiology and Biochemistry, 44(3), 1051-1063.
Wang, J. C. (2007). Evaluating therapeutic efficacy against cancer stem cells: new challenges posed by a new paradigm. Cell Stem Cell, 1(5), 497-501.
Wang, X., Jin, J., Wan, F., Zhao, L., Chu, H., Chen, C., Liao, G., Liu, J., Yu, Y., Teng, H., Fang, L., Jiang, C., Pan, W., Xie, X., Li, J., Lu, X., Jiang, X., Ge, X., Ye, D., & Wang, P. (2019). AMPK promotes SPOP-mediated NANOG degradation to regulate prostate cancer cell stemness. Developmental Cell, 48(3), 345-360.e347.
Watanabe, M., Ohnishi, Y., Inoue, H., Wato, M., Tanaka, A., Kakudo, K., & Nozaki, M. (2014). NANOG expression correlates with differentiation, metastasis and resistance to preoperative adjuvant therapy in oral squamous cell carcinoma. Oncology Letters, 7(1), 35-40.
Wefers, C., Schreibelt, G., Massuger, L. F., Vries, I. J. M., & Torensma, R. (2018). Immune curbing of cancer stem cells by CTLs directed to NANOG. Frontiers in Immunology, 9, 1412.
Wong, R. S. (2011). Apoptosis in cancer: From pathogenesis to treatment. Journal of Experimental & Clinical Cancer Research, 30(1), 87.
Wright, M. H., Calcagno, A. M., Salcido, C. D., Carlson, M. D., Ambudkar, S. V., & Varticovski, L. (2008). Brca1 breast tumors contain distinct CD44+/CD24-and CD133+ cells with cancer stem cell characteristics. Breast Cancer Research, 10(1), R10.
Xu, D.-D., Zhou, P.-J, Wang, Y., Zhang, Y., Zhang, R., Zhang, L., Chen, S.-H., Fu, W.-Y., Ruan, B.-B., Xu, H.-P., Hu, C.-Z., Tian, L., Qin, J.-H., Wang, S., Wang, X., Liu, Q.-Y., Ren, Z., Gu, X.-K., Li, Y.-H., … Wang, Y.-F. (2016). miR-150 suppresses the proliferation and tumorigenicity of leukemia stem cells by targeting the nanog signaling pathway. Frontiers in Pharmacology, 7, 439.
Xu, F., Dai, C., Zhang, R., Zhao, Y., Peng, S., & Jia, C. (2012). Nanog: A potential biomarker for liver metastasis of colorectal cancer. Digestive Diseases and Sciences, 57(9), 2340-2346.
Xu, X., Lu, Y., Li, Y., & Prinz, R. A. (2017). Sonic Hedgehog signaling in thyroid cancer. Frontiers in Endocrinology, 8, 284.
Yan, G. N., Yang, L., Lv, Y. F., Shi, Y., Shen, L. L., Yao, X. H., Guo, Q. N., Zhang, P., Cui, Y. H., Zhang, X., Bian, X. W., & Guo, D. Y. (2014). Endothelial cells promote stem-like phenotype of glioma cells through activating the Hedgehog pathway. The Journal of Pathology, 234(1), 11-22.
Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., Savagner, P., Gitelman, I., Richardson, A., & Weinberg, R. A. (2004). Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell, 117(7), 927-939.
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., & Cui, H. (2020). Targeting cancer stem cell pathways for cancer therapy. Signal Transduction and Targeted Therapy, 5(1), 1-35.
Yang, Z. J., Chee, C. E., Huang, S., & Sinicrope, F. A. (2011). The role of autophagy in cancer: therapeutic implications. Molecular Cancer Therapeutics, 10(9), 1533-1541.
Yin, X., Zhang, B.-H., Zheng, S.-S., Gao, D.-M., Qiu, S.-J., Wu, W.-Z., & Ren, Z.-G. (2015). Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling. Journal of Hematology & Oncology, 8(1), 23.
You, J. S., Kang, J. K., Seo, D.-W., Park, J. H., Park, J. W., Lee, J. C., Jeon, Y. J., Cho, E. J., & Han, J.-W. (2009). Depletion of embryonic stem cell signature by histone deacetylase inhibitor in NCCIT cells: involvement of Nanog suppression. Cancer Research, 69(14), 5716-5725.
Yu, C.-C., Chen, Y.-W., Chiou, G.-Y., Tsai, L.-L., Huang, P.-I., Chang, C.-Y., & Chou, M.-Y. (2011). MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. Oral Oncology, 47(3), 202-210.
Yu, Z., Baserga, R., Chen, L., Wang, C., Lisanti, M. P., & Pestell, R. G. (2010). microRNA, cell cycle, and human breast cancer. The American Journal of Pathology, 176(3), 1058-1064.
Yu, Z., Pestell, T., Lisanti, M., & Pestell, R. (2012). Cancer stem cells. The International Journal of Biochemistry & Cell Biology, 44(12), 2144-2151.
Zavadil, J., & Böttinger, E. P. (2005). TGF-β and epithelial-to-mesenchymal transitions. Oncogene, 24(37), 5764-5774.
Zbinden, M., Duquet, A., Lorente-Trigos, A., Ngwabyt, S. N., Borges, I., & i Altaba, A. R. (2010). NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. The EMBO Journal, 29(15), 2659-2674.
Zhan, Q. (2005). Gadd45a, a p53-and BRCA1-regulated stress protein, in cellular response to DNA damage. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 569(1-2), 133-143.
Zhan, Y.-y., He, J.-p., Chen, H.-z., Wang, W.-j., & Cai, J.-c. (2013). Orphan receptor TR3 is essential for the maintenance of stem-like properties in gastric cancer cells. Cancer Letters, 329(1), 37-44.
Zhang, C., Li, C., He, F., Cai, Y., & Yang, H. (2011). Identification of CD44+ CD24+ gastric cancer stem cells. Journal of Cancer Research and Clinical Oncology, 137(11), 1679-1686.
Zhang, J., Wang, X., Chen, B., Xiao, Z., Li, W., Lu, Y., & Dai, J. (2010). The human pluripotency gene NANOG/NANOGP8 is expressed in gastric cancer and associated with tumor development. Oncology Letters, 1(3), 457-463.
Zhang, J., Wang, X., Li, M., Han, J., Chen, B., Wang, B., & Dai, J. (2006). NANOGP8 is a retrogene expressed in cancers. The FEBS Journal, 273(8), 1723-1730.
Zhang, W., Sui, Y., Ni, J., & Yang, T. (2016). Insights into the Nanog gene: A propeller for stemness in primitive stem cells. International Journal of Biological Sciences, 12(11), 1372-1381.
Zhang, Z., Sun, L., Zhang, Y., Lu, G., Li, Y., & Wei, Z. (2018). Long non-coding RNA FEZF1-AS1 promotes breast cancer stemness and tumorigenesis via targeting miR-30a/Nanog axis. Journal of Cellular Physiology, 233(11), 8630-8638.
Zhao, Z., Bai, S., Wang, R., Xiong, S., Li, Y., Wang, X., Chen, W., & Cheng, B. (2019). Cancer-associated fibroblasts endow stem-like qualities to liver cancer cells by modulating autophagy. Cancer Management and Research, 11, 5737-5744.
Zhao, Y., Bao, Q., Renner, A., Camaj, P., Eichhorn, M., Ischenko, I., Angele, M., Kleespies, A., Jauch, K.-W., & Bruns, C. (2011). Cancer stem cells and angiogenesis. International Journal of Developmental Biology, 55(4-5), 477-482.
Zhao, W., Li, Y., & Zhang, X. (2017). Stemness-related markers in cancer. Cancer Translational Medicine, 3(3), 87.
Zhao, B., Luo, J., Wang, Y., Zhou, L., Che, J., Wang, F., Peng, S., Zhang, G., & Shang, P. (2019). Metformin Suppresses self-renewal ability and tumorigenicity of osteosarcoma stem cells via reactive oxygen species-mediated apoptosis and autophagy. Oxidative Medicine and Cellular Longevity, 2019, 9290728.
Zhou, J.-J., Deng, X.-G., He, X.-Y., Zhou, Y., Yu, M., Gao, W.-C., Zeng, Q.-B., Li, Z.-H., & Chen, R.-F. (2014). Knockdown of NANOG enhances chemosensitivity of liver cancer cells to doxorubicin by reducing MDR1 expression. International Journal of Oncology, 44(6), 2034-2040.
Zhou, S., Morris, J. J., Barnes, Y., Lan, L., Schuetz, J. D., & Sorrentino, B. P. (2002). Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proceedings of the National Academy of Sciences of the United States of America, 99(19), 12339-12344.
Zhou, S.-F., Wang, L.-L., Di, Y. M., Xue, C. C., Duan, W., Li, C. G., & Li, Y. (2008). Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Current Medicinal Chemistry, 15(20), 1981-2039.
Zhou, B.-B. S., Zhang, H., Damelin, M., Geles, K. G., Grindley, J. C., & Dirks, P. B. (2009). Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nature Reviews Drug Discovery, 8(10), 806-823.
Zhu, J.-Y., Yang, X., Chen, Y., Jiang, Y., Wang, S.-J., Li, Y., Wang, X.-Q., Meng, Y., Zhu, M.-M., Ma, X., Huang, C., Wu, R., Xie, C.-F., Li, X.-T., Geng, S.-S., Wu, J.-S., Zhong, C.-Y., & Han, H.-Y. (2017). Curcumin suppresses lung cancer stem cells via inhibiting Wnt/β-catenin and sonic hedgehog pathways. Phytotherapy Research, 31(4), 680-688.
Zhu, Y., Yu, F., Jiao, Y., Feng, J., Tang, W., Yao, H., Gong, C., Chen, J., Su, F., Zhang, Y., & Song, E. (2011). Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clinical Cancer Research, 17(22), 7105-7115.